Endovascular Treatment with Drug-Coated Balloons in Femoropopliteal Artery Disease

[Objectives]In this study, we aimed to evaluate the one-year follow-up findings of endovascular treatment with drug-covered balloon in patients with femoropopliteal artery disease (FAD).[Patients and Methods]From June 2012 to March 2015, 43 patients were enrolled in the study. Fifteen patients, 16 limbs and 19 lesions were treated with percutaneous transluminal angioplasty (PTA). Twenty-eight patients, 31 limbs and 36 lesions were treated with drug-coated balloon (DCB). At 12 months, all patients were examined with magnetic resonance angiography.[Results]Primary patency was seen in 47.4% of the treated lesions in the PTA group and 80.5% in the DCB group. There was statistically significant difference in primary patency between the groups (P = 0.011). Clinical improvement was seen in 56.3% of the treated limbs in the PTA group and 83.9% in the DCB group. There was no statistically significant difference in clinical improvement between the two groups (P = 0.075).[Conclusion]DCB with low restenosis rate can be used safely for endovascular treatment in patients with FAD as an alternative of standard balloon and stent.